a public good project by the
Synthesis
Company
of California

© 2026

C. Leonardi | doi.page

0 works0 citations0 h-index

C. Leonardi

Central Dermatology(US)Saint Louis University(US)

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Asthma and respiratory diseases, Pharmaceutical studies and practices

Most-Cited Works

→ European S3‐Guidelines on the systemic treatment of psoriasis vulgaris(2009)697 cited
→ A classification of psoriasis vulgaris according to phenotype(2006)290 cited
→ Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data(2019)284 cited
→ Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)(2018)186 cited
→ Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches(2018)146 cited
→ Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis(2011)127 cited

→ Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks(2007)120 cited

→ Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)(2014)115 cited

→ A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*(2020)112 cited

→ The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection(2012)94 cited